##plugins.themes.academic_pro.article.sidebar##

Download
pdf
Statistic
Read Counter : 1403 Download : 622

##plugins.themes.academic_pro.article.main##

Abstract

The role and importance of glial neurotrophic factor in the early detection of Parkinson's disease has been assessed. Depending on the clinical forms and duration of the disease, the amount of glial neurotrophic factor in the blood serum of patients was analyzed.

Keywords

Parkinson's disease GDNF neuron degeneration

##plugins.themes.academic_pro.article.details##

Creative Commons License

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.

How to Cite
Abdukodirov Eldor Isroilovich, Matmurodov Rustambek Jumanazarovich, Khalimova Khanifa Muxsinovna, Muminov Bekzod Askarovhch, & Naimov Olim Yunusovuch. (2022). The Role And Importance Of Gliah Neurotrophical Factors In Early Diagnosis Of Parkinson Disease. Texas Journal of Medical Science, 5, 1–6. https://doi.org/10.62480/tjms.2022.vol5.pp1-6
Crossref
Scopus
Google Scholar
Europe PMC

References

  1. S. Kucherenko, V. I. Petrenko, A. V. Kubyshkin, I. I. Fomochkina, L. E. Sorokina, V. V. Tkach, Yu. Study of the mechanisms of neurodegenerative processes in experimental metabolic syndrome // Medical Bulletin of the North Caucasus 2019. -T. 14. No. 1.2. - P.211-216.
  2. Litvinenko I.V., Krasakov I.V., Bisaga G.N., Skulyabin D.I., Poltavskiy I.D. The modern concept of the pathogenesis of neurodegenerative diseases and the strategy of therapy. Journal of Neurology and Psychiatry, 2017.- 6(2):.- P.1- 8.
  3. Khalimova Kh.M., Raimova M.M., Matmurodov R.Zh. The significance of various risk factors in the manifestation of Parkinson's disease // Journal of Neurology, 2009, No. 3, pp. 15-17.
  4. Khalimova Kh.M. The role of nitric oxide activity in the development of cognitive impairment in Parkinson's disease // Uzbekistan Tibbiyot Journal 2009, No. 6, P. 52-54.
  5. Khalimova Kh.M. Raimova M.M., Matmurodov R.Zh. The significance of biochemical factors in the development of cognitive impairment in Parkinson's disease // Journal of Neurology-2010, No. 2. pp. 26-29.
  6. Khalimova Kh.M., Raimova M.M., Matmurodoa R.Zh. Neurodegenerative diseases and nitric oxide // Uzbekistan Medical Journal, 2010, No. 6. pp. 64-68.
  7. Khalimova Kh.M., Raimova M.M., Matmurodov R.Zh., Molecular genetic studies of polymorphisms of the GSTM1 and GSTT1 genes in patients with Parkinson's disease in people of Uzbek nationality // Journal of Infection, Immunity, Pharmacology-2011, No. 3, C .32-35.
  8. Khalimova Kh.M., Raimova M.M., Matmurodov R.Zh. Molecular genetic analysis and risk factors for Parkinson's disease in people of Uzbek nationality / Proceedings of the II National Congress on Parkinson's disease and movement disorders (with international participation). Moscow, Scientific Center of Neurology of the Russian Academy of Medical Sciences, September 21-23, 2011, pp. 27-32.
  9. Khalimova Kh.M., Raimova M.M., Matmurodov R.Zh. Molecular genetic and some biochemical aspects of Parkinson's disease // International Neurological Journal, Ukraine, 2011, No. 1 (39), P. 91-94.
  10. Armstrong R.A. On the 'classification' of neurodegenerative disorders: discrete entities, overlap or continuum? // Folia Neuropathol. – 2012. – V. 50. № 3. - Р. 201- 208.
  11. Armstrong R.A. What causes Alzheimer's disease? // Folia Neuropathol. – 2013. – V. 51. № 3. - Р. 169-188.
  12. Amaral M., Outeiro T.F., Scrutton N.S., Giorgini F. The causative role and therapeutic potential of the kynurenine pathway in neurodegenerative disease // J. Mol. Med. (Berl). – 2013. – V. 91. № 6. - Р. 705-713.
  13. Amber L. Traugott, Jeffrey F. Moley. The RET Protooncogene // Endocrine Neoplasia. – 2009. - Volume 153 of the series Cancer Treatment and Research. - P. 303-319.
  14. Bartkowska, K. Neurotrophins and their receptors in early development of the mammalian nervous system / K. Bartkowska [et al.] // Acta Neurobiol. Exp. – 2010. – № 4. – Р. 424–426.
  15. Brunelli, A. Acute exercise modulates BDNF and pro-BDNF protein content in immune cells / A. Brunelli [et al.] // Med Sci Sports Exerc. – 2012. – Vol. 44, № 10. – P. 1771–1777.
  16. Cohen Cory, S., Kidane, A.H., Shirkey, N.J., and Marshak, S. (2010) Brainderived neurotrophic factor and the development of structural neuronal connectivity, Dev. Neurobiol., 70, 271–288.
  17. Dabidi, R.V. Endurance exercise training and direfully methane supplement: changes in neurotrophic factor and oxidative stress induced by lead in rat brain / R.V. Dabidi [et al.] // J. Biol Sport. – 2013. – V. 30, № 1. – P. 6–10.
  18. Duarte EP, Curcio M, Canzoniero LM, Duarte CB. Neuroprotection by GDNF in the ischemic brain // Growth Fac-tors. – 2012. – Vol. 30. - № 4. – P. 242-57.
  19. Isacson O, Kordower JH. Future of cell and gene therapies for Parkinson's disease // Ann Neurol. – 2008. – Vol. 64. - № 2. – P. 122-38.
  20. Gurgis, F.M. Mitogen-activated protein kinase-activated protein kinase 2 in neuroinflammation, heat shock protein 27 phosphorylation, and cell cycle: role and targeting / F.M. Gurgis [et al.] // J. Neurobiol. – 2013. – Vol. 85, № 2. – P. 145–156.
  21. Japón M.A., Urbano A.G., Sáez C, Segura D.I., Cerro A.L, Diéguez C., Alvarez C.V. Glial - derived neurotropic factor and RET gene expression in normal human anterior pituitary cell types and in pituitary tumors // J Clin.Endocrino.Metab. – 2002. – Vol. 87. -№ 4. P. 1879-84.
  22. Jiang, L.; Zhang, H.; Wang, C.; Ming, F.; Shi, X.; Yang, M. Serum level of brain-derived neurotrophic factor in Parkinson’s disease: A meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry 2019, 88, 168–174.
  23. Hoyng, S.A., Tannemaat, M.R., De Winter, F., Verhaagen, J., and Malessy, M.J. (2011) Nerve surgery and gene therapy: a neurobiological and clinical perspective, J. Hand. Surg. Eur., 36, 735–746.
  24. Ming-Yu.Shi, Cheng-Cheng Ma, Fang-Fang Chen, Xiao-Yu Zhou, Xue Li, Chuan-Xi Tang, Lin Zhang, Dian-Shuai Gao. Possible role of glial cell line-derived neurotrophic factor for predicting cognitive impairment in Parkinson’s disease: a case-control study // J, Neural regeneration research.-2021,- Vol. 16.-Issuse 5-P.885-892.
  25. Peterson, J.L. The role of endogenous epidermal growth factor receptor ligands in mediating corneal epithelial homeostasis / J.L Peterson [et al.] // Invest Ophthalmol. – 2014. – V.55, № 5. – P. 75–80.
  26. Rahmani, A. Dehydroepiandrosterone stimulates nerve growth factor and brain derived neurotrophic factor in cortical neurons / A. Rahmani [et al.] // Adv Pharmacol Sci. – 2013. – № 2. – P. 87–88.
  27. Sariola H., Saarma M. Novel functions and signaling pathways for GDNF. J Cell Sci. 2003. Vol. 116. № 19.P. 3855–3862.
  28. Shabtay-Orbach A, Amit M, Binenbaum Y, Na'ara S, Gil Z. Paracrine regulation of glioma cells invasion by astrocytes is mediated by glial-derived neurotrophic factor. Int J Cancer. 2015. Vol. 137. № 5. P. 1012-20.
  29. Tonchev, A.B. Brain ischemia, neurogenesis, and neurotrophic receptor expression in prima- test / A.B. Tonchev [et al.] // Arch Ital. Biol. – 2011. – Vol. 149, № 2. – P. 25–31.
  30. Traugott A.L., Moley J.F. The RET protooncogene // CancerTreatRes. – 2010. Vol. 153. - P. 303–319.
  31. Wang, Y. BDNF and NT-3 expression by using glucocorticoid-induced bicistronic expression vector pGC-BDNF-IRES-NT3 protects apoptotic cells in a cellular injury model / Y. Wang [et al.] // Brain Res. – 2012. – № 11. – P. 133–137.
  32. Wang X. Structural studies of GDNF family ligands with their receptors-Insights into ligand recognitionand activation of receptor tyrosine kinase RET // Biochim.Biophys.Acta. – 2013. – Vol. 1834. - № 10. – P. 2205-12.
  33. Wang, N. Puerarin protected the brain from cerebral ischemia injury via astrocyte apoptosis inhibition / N.Wang [et al.] // J.Neuropharmacology. – 2014. – Vol.70, № 4. – Р. 54–67.
  34. Wiesenhofer B, Stockhammer G, Kostron H, Maier H, Hinterhuber H, Humpel C. Glial cell line-derived neurotrophic factor (GDNF) and its receptor (GFR-alpha 1) are strongly expressed in human gliomas // Acta.Neuropathologia. – 2000.–Vol.99. - № 2. P.131-137.